Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132716) titled 'Randomized, open label, single dose, two cycle, double crossover fasting bioequivalence trial of fluconazole dry suspension in healthy subjects' on Sept. 17.
Study Type: Interventional study
Study Design:
Cross-over
Primary Sponsor: Zhejiang Hospital
Condition:
This product is a broad-spectrum triazole antifungal medication, suitable for treating the following fungal infections in adult patients and children aged 2 years and older: 1. Invasive aspergillosis. 2. Candidemia in non-neutropenic patients. 3. Severe invasive infections caused by Candida resistant to fluconazole (including Candida krusei). 4. ...